Terns Pharmaceuticals/$TERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.
Ticker
$TERN
Sector
Primary listing
Employees
59
Headquarters
Website
TERN Metrics
BasicAdvanced
$6.1bn
-
-$1.03
-0.38
-
Price and volume
Market cap
$6.1bn
Beta
-0.38
52-week high
$53.19
52-week low
$2.66
Average daily volume
9.5m
Financial strength
Current ratio
62.409
Quick ratio
62.091
Long term debt to equity
0.044
Total debt to equity
0.091
Profitability
EBITDA (TTM)
-110.034
Effective tax rate (TTM)
-0.61%
Management effectiveness
Return on assets (TTM)
-9.91%
Return on equity (TTM)
-14.23%
Valuation
Price to book
5.9
Price to tangible book (TTM)
5.9
Price to free cash flow (TTM)
-59.964
Free cash flow yield (TTM)
-1.67%
Free cash flow per share (TTM)
-0.882
Growth
Earnings per share change (TTM)
-7.60%
3-year earnings per share growth (CAGR)
-14.89%
What the Analysts think about TERN
Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.
TERN Financial Performance
Revenues and expenses
TERN Earnings Performance
Company profitability
TERN News
AllArticlesVideos
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Business Wire·20 hours ago
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
Business Wire·2 weeks ago
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Terns Pharmaceuticals stock?
Terns Pharmaceuticals (TERN) has a market cap of $6.1B as of April 25, 2026.
What is the P/E ratio for Terns Pharmaceuticals stock?
The price to earnings (P/E) ratio for Terns Pharmaceuticals (TERN) stock is 0 as of April 25, 2026.
Does Terns Pharmaceuticals stock pay dividends?
No, Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders as of April 25, 2026.
When is the next Terns Pharmaceuticals dividend payment date?
Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Terns Pharmaceuticals?
Terns Pharmaceuticals (TERN) has a beta rating of -0.38. This means that it has an inverse relation to market volatility.